PREDICTGEN
Live / Applied — Fourth extension granted (statement of use) (as of 05 Nov 2025)
What this means for you
Not registered yet, but its 28 Oct 2021 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97096948
- Mark type
- Stylized text
- Filed
- 28 Oct 2021
- Published for opposition
- 19 Sept 2023
- Attorney of record
- ROGER H. BORA
Goods and services
- Class 042 — Scientific and technological services: Scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of blood samples for the purpose of drug development by others, namely, data-driven analytics and reporting to developers of drugs; scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of blood samples for the purpose of improving quality in the field of healthcare services, specifically for improving the monitoring and diagnostics of quantitative patient drug exposure, the monitoring and diagnostics of patient drug compliance, data-driven analytics and reporting to providers of healthcare services in the field of pharmacovigilance activities, drug dosage recommendations, initial drug prescribing, and drug switching, all for research purposes and not for medical purposes; scientific and technological services in the field of pharmaceuticals featuring pharmacogenomic testing analysis and evaluation of buccal, saliva and other biological samples for the purposes of analyzing how an individual's genetic and non-genetic factors affect their response to drugs, improving drug selection and dosage recommendations, selecting initial and subsequent medications, identifying drug-drug interactions, avoiding adverse drug reactions, developing clinical treatment decision support recommendations, and supporting other medical diagnostic products and prescription drugs; scientific and technological services in the field of pharmaceuticals, namely, scientific testing, research, and analysis for the purpose of determining a patient's disease and drug response phenotype through evaluation of chromatin state, genomic regulatory elements, epigenomics, proteomics, metabolomics, transcriptomics, environmental factors, sociological factors, age, biological sex, ethnicity, and other non-genetic factors to predict pharmacological drug efficacy and adverse drug reaction phenotypes for patients; scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of buccal, saliva, blood and other biological samples for the purposes of supporting drug clinical trials and research into the field of new drug development and drug repurposing
Owner
- Phenomics Health Inc., Plymouth, MI, US
- Phenomics Health Inc., Plymouth, MI, US
Prosecution history
- 06 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 Nov 2025 — SOU EXTENSION 4 GRANTED
- 05 Nov 2025 — SOU EXTENSION 4 FILED
- 05 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 26 Apr 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Apr 2025 — SOU EXTENSION 3 GRANTED
- 25 Apr 2025 — SOU EXTENSION 3 FILED
- 25 Apr 2025 — SOU TEAS EXTENSION RECEIVED
- 13 Nov 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Nov 2024 — SOU EXTENSION 2 GRANTED
- 13 Nov 2024 — SOU EXTENSION 2 FILED
- 13 Nov 2024 — SOU TEAS EXTENSION RECEIVED
- 11 May 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 May 2024 — SOU EXTENSION 1 GRANTED
- 10 May 2024 — SOU EXTENSION 1 FILED